Cosmo Pharmaceuticals has reported successful outcomes from two phase 3 trials of their topical solution, clascoterone 5%, for hair loss. This treatment targets androgen receptors at the hair follicles, offering a new approach to hair loss treatment without the side effects of systemic hormonal exposure. The trials demonstrated significant hair growth and patient satisfaction.
